
GlaxoSmithKline plc GSK
$ 48.98
0.68%
Annual report 2024
added 01-24-2026
GlaxoSmithKline plc Interest Expense 2011-2026 | GSK
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense GlaxoSmithKline plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 912 M | 775 M | 888 M | - | - | - | - | - | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 912 M | 775 M | 858 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
1.11 M | $ 2.62 | 28.82 % | $ 147 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.51 | 7.34 % | $ 8.45 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
4.08 M | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Galapagos NV
GLPG
|
911 K | $ 34.61 | 0.61 % | $ 2.69 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
-3.96 M | $ 24.45 | 4.49 % | $ 2.21 B | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 3.1 | 4.49 % | $ 908 M | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 235.41 | 2.95 % | $ 5 B | ||
|
BioXcel Therapeutics
BTAI
|
20.2 M | $ 1.84 | 1.66 % | $ 4.66 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
5.26 M | $ 67.49 | -3.02 % | $ 9.03 B | ||
|
Brickell Biotech
BBI
|
5 K | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 4.51 | 8.41 % | $ 9.81 B | ||
|
BeiGene, Ltd.
BGNE
|
-12.6 M | - | 0.49 % | $ 251 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.66 M | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Coherus BioSciences
CHRS
|
40.5 M | $ 2.04 | 28.3 % | $ 192 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
250 M | $ 171.89 | -1.1 % | $ 25 B | ||
|
BioVie
BIVI
|
4.3 M | $ 1.2 | -3.7 % | $ 1.77 M |